Quite Favorable Media Coverage Unlikely to Influence Trinity Biotech Stock Price (TRIB)

Press articles on Trinity Biotech (NASDAQ: TRIB) were pretty positive this week, reports Accern. Accern ranks corporate coverage on a scale ranging from negative to positive, with the closest scores being the most favorable. Trinity Biotech scored a score of 0.09 on the Accern scale. Accern also awarded the media an impact score of 46.2655165820746 out of 100, which means that recent media coverage is not expected to have any impact on the course of action in the near future.

Trinity Biotech shares depreciated by $ 0.09 The company recorded a trading volume of 207,946 shares, compared to its average volume of 29,462. The company has a market capitalization of $ 101. .51 million, a P / E ratio of 30.31 and a beta of 1.31. The company has a current ratio of 5.23, a ratio of 3.49 and a debt ratio of 1.43. Trinity Biotech reached its lowest level in 52 weeks of $ 4.22 and its highest level in 52 weeks of $ 6.54.

Trinity Biotech (NASDAQ: TRIB) released its financial results for the last time on Thursday, July 19th. The company reported earnings per share (EPS) of $ 0.03 for the quarter, compared with $ 0.06 for Zacks' consensus estimate ($ 0.03). The company achieved a turnover of $ 25.00 million during the quarter. Trinity Biotech recorded a negative net margin of 41.88% and a positive return on equity of 3.59%.

A number of research firms have recently published reports on TRIB. ValuEngine lowered Trinity Biotech from a "buy" rating to a "hold" rating in a report on Tuesday, July 17th. Zacks Investment Research downgraded Trinity Biotech from a note of "hold" to a "sell" note in a report released on Friday, April 13.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures and markets diagnostic medical products for laboratories and service points (POCs) in the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instruments, that detect infectious diseases, such as Lyme disease, badually transmitted diseases, respiratory infections, epstein barr virus and other infectious diseases. Other viral pathogens; and products for the in vitro diagnostic test of hemoglobin A1c used in the surveillance and diagnosis of diabetes, and the identification of people at high risk of developing diabetes.

Further Reading: Dividend

Receive news and ratings for Trinity Biotech Daily – Enter your email address below to receive a concise summary Latest news and badyst estimates for Trinity Biotech and related companies with MarketBeat .com FREE Daily eNewsletter.